Songfeng Chen

Dr. Songfeng Chen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
QZQianjun Zhuang
Qianjun Zhuang
SCSongfeng Chen
Songfeng Chen
XZXuyu Zhou
Xuyu Zhou
XJXingyu Jia
Xingyu Jia
MZMengyu Zhang
Mengyu Zhang
YXYinglian Xiao
Yinglian Xiao
INTRODUCTION: Los Angeles grade C/D esophagitis is a severe manifestation of gastroesophageal reflux disease that require active treatment and close follow-up. Potassium competitive acid blockers (P-CAB) are promising alternatives to proton pump inhibitors (PPI). We aimed to compare the efficacy and safety of P-CAB and PPI in healing grade C/D esophagitis to aid clinical decision-making. METHODS: A systematic literature search was performed using PubMed, MEDLINE, and Cochrane Central Register of Controlled Trials. Randomized controlled trials were eligible for inclusion if efficacy of P-CAB and PPI in healing grade C/D esophagitis was reported. Pooled risk ratios and risk difference with 95% credible intervals were used to summarize estimated effect of each comparison. The benefit of treatments was ranked using the surface under the cumulative probability ranking score. RESULTS: Of 5,876 articles identified in the database, 24 studies were eligible. Studies included incorporated 3 P-CAB (vonoprazan, tegoprazan, and keverprazan) and 6 PPI (lansoprazole, esomeprazole, omeprazole, rabeprazole extended-release (ER), pantoprazole, and dexlansoprazole). Based on the failure to achieve mucosal healing, 20 mg of vonoprazan q.d. ranked the first among PPI in initial and maintained healing of grade C/D esophagitis (surface under the cumulative probability ranking score = 0.89 and 0.87, respectively). Vonoprazan had similar risk of incurring adverse events, severe adverse events, and withdrawal to drug when compared with PPI. For those who attempted lower maintenance treatment dose, 10 mg of vonoprazan q.d. was a reasonable choice, considering its moderate efficacy and safety. DISCUSSION: Vonoprazan has considerable efficacy in initial and maintained healing of grade C/D esophagitis compared with PPI, with moderate short-term and long-term safety.

30 April 2023 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
XJXingyu Jia
Xingyu Jia
SCSongfeng Chen
Songfeng Chen
QZQianjun Zhuang
Qianjun Zhuang
NTNiandi Tan
Niandi Tan
MZMengyu Zhang
Mengyu Zhang
YXYinglian Xiao
Yinglian Xiao
Xingyu Jia, Songfeng Chen, Qianjun Zhuang, Niandi Tan, Mengyu Zhang, Yi Cui, Jinhui Wang, Xiangbin Xing, and Yinglian Xiao*. J Neurogastroenterol Motil 2023;29:145-55. https://doi.org/10.5056/jnm22176

1 August 2021 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
SCSongfeng Chen
Songfeng Chen
MZMengyu Zhang
Mengyu Zhang
MLMengya Liang
Mengya Liang
NTNiandi Tan
Niandi Tan
Yi CuiYi Cui
Yi Cui
YXYinglian Xiao
Yinglian Xiao
INTRODUCTION: Achalasia is a primary esophageal motility disorder with heterogeneous manometric subtypes and prognosis, characterized by degeneration of the esophageal myenteric plexus, and reduction in interstitial cells of Cajal (ICCs). This study aimed to explore the histopathologic characteristics of lower esophageal sphincter (LES) muscle from patients with achalasia with different subtypes and different prognosis. METHODS: We examined specimens of LES muscle from 122 patients with achalasia who underwent peroral endoscopic myotomy and from 10 control patients who underwent esophagectomy for esophageal cancer. Hematoxylin–eosin staining was performed to assess inflammation infiltration, fibrosis, and atrophy. Specific immunohistochemical staining was performed to identify ICCs and neuronal nitric oxide synthase (nNOS). RESULTS: The number of ICCs in patients with type I achalasia was significantly lower than that in patients with type II achalasia, followed by that in control patients (type I vs type II vs control group= 0.4 vs 1.2 vs 9.5; P < 0.001). The number of nNOS-positive cells was significantly lower in patients with achalasia than that in control patients (type I vs type II vs control group = 0.0 vs 0.0 vs 8.0; P < 0.001). Nonrecurrent group had significantly more ICCs than recurrent group (type I: nonrecurrent vs recurrent = 1.0 vs 0.1; P = 0.010; type II: nonrecurrent vs recurrent = 2.0 vs 0.4; P = 0.004). DISCUSSION: ICCs and nNOS-positive cells reduced significantly in LES muscle of patients with achalasia. The number of ICCs differed among different achalasia subtypes and was related to patients' clinical prognosis.

27 November 2023 in Journal of Digestive Diseases
Verified
Journal Article
Closed access
JHJun Nan Hu
Jun Nan Hu
SCSongfeng Chen
Songfeng Chen
XJXing Yu Jia
Xing Yu Jia
YLYu Luo
Yu Luo
XXXiang Bin Xing
Xiang Bin Xing
YXYing Lian Xiao
Ying Lian Xiao

30 April 2025 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
SCSongfeng Chen
Songfeng Chen
XJXingyu Jia
Xingyu Jia
QZQianjun Zhuang
Qianjun Zhuang
XHXun Hou
Xun Hou
KSKewin T H Siah
Kewin T H Siah
YXYinglian Xiao
Yinglian Xiao
Songfeng Chen, Xingyu Jia, Qianjun Zhuang, Xun Hou, Kewin T H Siah, Mengyu Zhang, Fangfei Chen, Niandi Tan, Junnan Hu, and Yinglian Xiao. J Neurogastroenterol Motil 2025;31:218-26. https://doi.org/10.5056/jnm24091

3 October 2023 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
XJXingyu Jia
Xingyu Jia
SCSongfeng Chen
Songfeng Chen
XHXun Hou
Xun Hou
QZQianjun Zhuang
Qianjun Zhuang
NTNiandi Tan
Niandi Tan
YXYinglian Xiao
Yinglian Xiao
INTRODUCTION: Currently, the diagnosis of achalasia mainly relies on invasive or radioactive examinations. This study aimed to develop a noninvasive diagnostic method for achalasia based on specific serum markers. METHODS: Serum levels of profilin-1, galectin-10, immunoglobulin heavy variable 3–9, vasodilator-stimulated phosphoprotein, and transgelin-2 were measured in patients with achalasia and controls by enzyme-linked immunosorbent assay. The diagnostic values and thresholds were determined by the receiver operating characteristic curve analysis. Then, patients with dysphagia were prospectively enrolled to validate the ability of these molecules for achalasia diagnosing. RESULTS: A total of 142 patients with achalasia and 50 nonachalasia controls (healthy volunteers and patients with reflux esophagitis) were retrospectively included. The serum levels of profilin-1, galectin-10, and transgelin-2 in patients with achalasia were significantly higher than those in healthy volunteers and patients with reflux esophagitis (P all < 0.001). Profilin-1, galectin-10, and transgelin-2 were of good performance in diagnosing achalasia, with optimal thresholds of 2,171.2, 33.9, and 1,630.6 pg/mL, respectively. Second, 40 patients with dysphagia were prospectively enrolled to the validation of achalasia. For profilin-1, the positive predictive value, negative predictive value, sensitivity, and specificity were 100.0%, 64.5%, 45.0%, and 100.0%, respectively. The figures for transgelin-2 were 65.5%, 90.9%, 95.0%, and 50.0%. When both increased, the positive predictive value reached to 100.0%. When both indexes were normal, the negative predictive value was 100.0%. DISCUSSION: Profilin-1 and transgelin-2 were promising biomarkers for achalasia diagnosis and performed better in combination. Further multicenter studies are necessary to verify their application as preliminary screening tools for achalasia.